TP53 and cancer: Furthermore, RNA-seq data analysis revealed that RC48 and CM combination treatment affected key cancer-related pathways, including the mTOR signaling pathway, MAPK signaling pathway, FOXO signaling pathway, cell cycle, and p53 signaling pathway.